Found: 91
Select item for more details and to access through your institution.
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 5, p. 1324, doi. 10.1007/s10637-021-01104-7
- By:
- Publication type:
- Article
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 3, p. 265, doi. 10.1007/s10637-006-9020-9
- By:
- Publication type:
- Article
The natural history of untreated muscle‐invasive bladder cancer.
- Published in:
- BJU International, 2020, v. 125, n. 2, p. 270, doi. 10.1111/bju.14872
- By:
- Publication type:
- Article
Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma.
- Published in:
- BJU International, 2019, v. 124, n. 4, p. 665, doi. 10.1111/bju.14719
- By:
- Publication type:
- Article
Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancer.
- Published in:
- BJU International, 2019, v. 124, n. 2, p. 290, doi. 10.1111/bju.14685
- By:
- Publication type:
- Article
Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer ( mCRPC).
- Published in:
- BJU International, 2015, v. 116, n. 1, p. 17, doi. 10.1111/bju.12867
- By:
- Publication type:
- Article
Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
- Published in:
- BJU International, 2015, v. 115, n. 7, p. 17, doi. 10.1111/bju.12867
- By:
- Publication type:
- Article
Radiographic progression by Prostate Cancer Working Group ( PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
- Published in:
- BJU International, 2014, v. 114, n. 6b, p. E25, doi. 10.1111/bju.12589
- By:
- Publication type:
- Article
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC.
- Published in:
- Science Translational Medicine, 2020, v. 12, n. 548, p. 1, doi. 10.1126/scitranslmed.abc4220
- By:
- Publication type:
- Article
Benchmarking Maintenance Therapy Survival in First-Line Platinum-Based Chemotherapy–Treated Patients with Advanced Urothelial Carcinoma Using Simulated Disease Modeling.
- Published in:
- Clinical Epidemiology, 2023, v. 15, p. 765, doi. 10.2147/CLEP.S409791
- By:
- Publication type:
- Article
Oncology Simulation Model: A Comprehensive and Innovative Approach to Estimate and Project Prevalence and Survival in Oncology.
- Published in:
- Clinical Epidemiology, 2022, v. 14, p. 1375, doi. 10.2147/CLEP.S377093
- By:
- Publication type:
- Article
Clinical trial awareness: Changes over time and sociodemographic disparities.
- Published in:
- Clinical Trials, 2015, v. 12, n. 3, p. 215, doi. 10.1177/1740774515571917
- By:
- Publication type:
- Article
A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles.
- Published in:
- Genome Medicine, 2020, v. 12, n. 1, p. 1, doi. 10.1186/s13073-020-0720-0
- By:
- Publication type:
- Article
Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies.
- Published in:
- Trials, 2015, v. 16, n. 1, p. 1, doi. 10.1186/s13063-015-0885-9
- By:
- Publication type:
- Article
Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies.
- Published in:
- Trials, 2015, v. 16, n. 1, p. 341, doi. 10.1186/s13063-015-0885-9
- By:
- Publication type:
- Article
The Case of Adjuvant Chemotherapy for Bladder Cancer.
- Published in:
- AUANews, 2017, v. 22, n. 4, p. 16
- By:
- Publication type:
- Article
Arterial Thromboembolism in Cancer Patients Treated With Cisplatin: A Systematic Review and Meta-analysis.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2012, v. 104, n. 23, p. 1837, doi. 10.1093/jnci/djs435
- By:
- Publication type:
- Article
Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Metabolic disease and adverse events from immune checkpoint inhibitors.
- Published in:
- European Journal of Endocrinology, 2021, v. 184, n. 6, p. 857, doi. 10.1530/EJE-20-1362
- By:
- Publication type:
- Article
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
- Published in:
- Oncology, 2016, v. 91, n. 5, p. 251, doi. 10.1159/000448621
- By:
- Publication type:
- Article
Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Use of Crowdsourcing for Cancer Clinical Trial Development.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 10, p. 1, doi. 10.1093/jnci/dju258
- By:
- Publication type:
- Article
Use of crowdsourcing for cancer clinical trial development.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Use of Crowdsourcing for Cancer Clinical Trial Development.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 10, p. 1, doi. 10.1093/jnci/dju258
- By:
- Publication type:
- Article
Adult Cancer Clinical Trials That Fail to Complete: An Epidemic?
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 9, p. 1, doi. 10.1093/jnci/dju229
- By:
- Publication type:
- Article
Concurrent diabetes mellitus may negatively influence clinical progression and response to androgen deprivation therapy in patients with advanced prostate cancer.
- Published in:
- Frontiers in Oncology, 2015, p. 1, doi. 10.3389/fonc.2015.00129
- By:
- Publication type:
- Article
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.
- Published in:
- Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-05992-x
- By:
- Publication type:
- Article
Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses.
- Published in:
- International Journal of Clinical Oncology, 2019, v. 24, n. 9, p. 1089, doi. 10.1007/s10147-019-01450-w
- By:
- Publication type:
- Article
Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 7, p. 2833, doi. 10.1007/s00432-022-04159-y
- By:
- Publication type:
- Article
The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.
- Published in:
- Clinical & Applied Thrombosis/Hemostasis, 2017, v. 23, n. 7, p. 755, doi. 10.1177/1076029616668405
- By:
- Publication type:
- Article
Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Oncologist, 2023, v. 28, n. 4, p. 366, doi. 10.1093/oncolo/oyac224
- By:
- Publication type:
- Article
Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma.
- Published in:
- Oncologist, 2022, v. 27, n. 6, p. 432, doi. 10.1093/oncolo/oyab075
- By:
- Publication type:
- Article
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.
- Published in:
- Oncologist, 2021, v. 26, n. 12, p. 1026, doi. 10.1002/onco.13925
- By:
- Publication type:
- Article
Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real‐World Practice.
- Published in:
- Oncologist, 2019, v. 24, n. 6, p. e397, doi. 10.1634/theoncologist.2019-0039
- By:
- Publication type:
- Article
Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors.
- Published in:
- Oncologist, 2018, v. 23, n. 12, p. 1494, doi. 10.1634/theoncologist.2018-0003
- By:
- Publication type:
- Article
A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.
- Published in:
- Oncologist, 2017, v. 22, n. 5, p. 609, doi. 10.1634/theoncologist.2016-0319
- By:
- Publication type:
- Article
Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide as First-Line Therapy in Patients With Metastatic Urothelial Carcinoma.
- Published in:
- Oncologist, 2014, v. 19, n. 9, p. 915, doi. 10.1634/theoncologist.2014-0153
- By:
- Publication type:
- Article
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 1, p. 186, doi. 10.1002/cam4.986
- By:
- Publication type:
- Article
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
- Published in:
- Acta Oncologica, 2018, v. 57, n. 4, p. 491, doi. 10.1080/0284186X.2017.1369565
- By:
- Publication type:
- Article
Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 9, p. 1642, doi. 10.1002/cncr.35179
- By:
- Publication type:
- Article
Adjuvant immunotherapy in patients with high‐risk muscle‐invasive urothelial carcinoma: The potential impact of informative censoring.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 15, p. 2892, doi. 10.1002/cncr.34255
- By:
- Publication type:
- Article
The impact of the globalization of cancer clinical trials on the enrollment of Black patients.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
- Published in:
- World Journal of Urology, 2019, v. 37, n. 1, p. 95, doi. 10.1007/s00345-018-2486-1
- By:
- Publication type:
- Article
Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer.
- Published in:
- World Journal of Urology, 2018, v. 36, n. 11, p. 1741, doi. 10.1007/s00345-018-2359-7
- By:
- Publication type:
- Article
Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.
- Published in:
- World Journal of Urology, 2013, v. 31, n. 6, p. 1535, doi. 10.1007/s00345-012-1001-3
- By:
- Publication type:
- Article
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
- Published in:
- BJU International, 2014, v. 113, n. 5b, p. E137, doi. 10.1111/bju.12564
- By:
- Publication type:
- Article
Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.
- Published in:
- BJU International, 2012, v. 110, n. 11b, p. E461, doi. 10.1111/j.1464-410X.2012.11148.x
- By:
- Publication type:
- Article